Atara Biotherapeutics, Inc.
2659 Townsgate Road
Suite 236
Thousand Oaks
California
91361
United States
211 articles with Atara Biotherapeutics, Inc.
-
Patient enrollment for the clinical trial, which was testing Atara’s autologous chimeric antigen receptor (CAR) T-cell immunology therapy called ATA2271, has been paused.
-
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
2/17/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2021 financial results after market close on Monday, February 28, 2022.
-
The fund will be used to target partnerships with promising early-stage biotechnology to enhance Fujifilm's life sciences portfolio.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Feb 07, 2022
2/7/2022
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 31,730 restricted stock units of Atara’s common stock to 10 newly hired employees and stock options to purchase an aggregate of 30,819 shares of Atara’s common stock to four such newly hired employees.
-
Fujifilm announced that it is acquiring Atara Biotherapeutics' cell therapy manufacturing facility in California for $100 million.
-
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
1/26/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB).
-
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis
1/24/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today lauded the second high impact study this month solidifying EBV as the primary driver of the development of MS.
-
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
-
Imeka Collaborates with Atara Biotherapeutics to Provide Neuroimaging for Phase 2 Study in Multiple Sclerosis
1/11/2022
Imeka, the leading neuroimaging company combining diffusion imaging and AI to map white matter integrity, today announced a collaboration with Atara Biotherapeutics, Inc. to utilize Imeka's novel biomarker technology in a Phase 2 clinical study of patients with progressive forms of multiple sclerosis (MS).
-
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
1/10/2022
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40 th Annual J.P. Morgan Healthcare Conference.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 07, 2022
1/7/2022
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 57,164 restricted stock units of Atara’s common stock to 12 newly hired employees and stock options to purchase an aggregate of 64,925 shares of Atara’s common stock to seven such newly hired employees.
-
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
1/6/2022
Be The Match BioTherapies and Atara Biotherapeutics, Inc., announced an extension of their collaboration to provide high-quality healthy donor cells for Atara’s off-the-shelf T-cell immunotherapy platform for patients with cancer and autoimmune diseases.
-
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
12/14/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced efficacy and safety results from its Phase 3 multicenter ALLELE study investigating tabelecleucel (tab-cel®) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).
-
The 63rd ASH Annual Meeting and Exposition is wrapping up today, with dozens providing updates on clinical trials and preclinical research. Here’s a highlight of just a few of those stories.
-
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
12/9/2021
Atara Biotherapeutics, Inc. today announced new preclinical and preliminary clinical results for ATA2271, a next-generation autologous chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin (MSLN).
-
Atara Biotherapeutics Reported Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3/2021
Atara Biotherapeutics, Inc. today reported the grant of an aggregate of 21,438 restricted stock units of Atara’s common stock to seven newly hired employees and stock options to purchase an aggregate of 24,017 shares.
-
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
11/30/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the Marketing Authorization Application (MAA) for tabelecleucel (tab-cel®) has been fully validated by the European Medicines Agency (EMA).
-
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences - Nov 08, 2021
11/8/2021
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced that Pascal Touchon, President and Chief Executive Officer of Atara, will participate at three upcoming virtual conferences.